News from all angles
(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network